At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,200 enrolled
Drug / intervention
Hydrochlorothiazide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Genetic Epidemiology of Responses to Antihypertensives
In Brief
An observational study evaluating Hydrochlorothiazide and Candesartan for Cardiovascular Diseases and 2 related conditions. Completed, enrolled 1,200 participants across 1 site.
Detailed Summary
To determine whether measured variation in genes coding for components of vasoconstriction and volume regulating systems predict interindividual differences in blood pressure response to therapy with a thiazide diuretic, hydrochlorothiazide, or an angiotensin II receptor blocker, candesartan, in hypertensive African-Americans (N=300 treated with each drug) and in hypertensive European Americans (N=300 treated with each drug).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCardiovascular Diseases, Heart Diseases, Hypertension
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)
Timeline
N/ACompletedFinished
1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 1997
First PostedMay 2000
Primary CompletionJan 2008
TodayJul 2026
First PostedMay 26, 2000
Enrollment StartFeb 1, 1997
Primary CompletionJan 1, 2008
TodayJul 2, 2026
Enrollment to primary: 10.9 yearsPosted 26.1 years ago
Interventions
Hydrochlorothiazidedrug
Candesartandrug